期刊文献+

乙型肝炎病毒感染者血清HBV DNA水平与HDL-C的相关性 被引量:1

Association between serum hepatitis B virus DNA level with high density lipoprotein cholesterol in patients with hepatitis B virus infection
原文传递
导出
摘要 目的分析乙型肝炎病毒(HBV)感染者血清HBV DNA和高密度脂蛋白胆固醇(HDL-C)水平,探讨血清HBV DNA拷贝数与HDL-C水平的相关性。方法收集116例HBV感染者血清,通过实时荧光定量PCR法测定血清HBV DNA拷贝数,通过选择性抑制均相测定法分析血清HDL-C值;计算HBVDNA拷贝数与HDL-C的相关系数,并对相关系数进行显著性检验。结果在乙型肝炎病毒感染者中,血清HBV DNA拷贝数对数均值为(4.18±1.77)/ml,分布范围为(1.38~7.85)/ml;血清HDL-C浓度均值为(1.30±0.29)mmol/L,分布范围为(0.66~2.01)mmol/L。血清HBVDNA拷贝数与HDL-C水平存在负相关(r=-0.5346,P=0.0023)。结论 HDL-C对乙型肝炎病毒的复制有抑制作用。 Objective To analyze serum hepatitis B virus DNA copies and high density lipoprotein cholesterol levels in patients with hepatitis B virus infection,and explore the association between virus DNA copies and high density lipoprotein cholesterol levels. Methods Serum samples were collected from 116 patients with hepatitis B virus infection. Serum hepatitis B virus DNA copies were determined by real-time quantitative polymerase chain reaction. High density lipoprotein cholesterol levels were measured with selective inhibition enzymatic methods. Correlation coefficient between serum hepatitis B virus DNA copies and high density lipoprotein cholesterol levels was calculated. Result Serum hepatitis B virus DNA copies were inversely correlated with high density lipoprotein cholesterol levels (r=-0.5346,P=0.0023) for patients with hepatitis B virus infection. Conclusion High density lipoprotein cholesterol may inhibit hepatitis B virus replication.
出处 《热带医学杂志》 CAS 2012年第10期1202-1204,共3页 Journal of Tropical Medicine
基金 深圳市宝安区科技计划项目(2010594)
关键词 乙型肝炎病毒 DNA拷贝数 高密度脂蛋白胆固醇 hepatitis B virus DNA copy high density lipoprotein cholesterol
  • 相关文献

参考文献13

  • 1Chemin I, Guillaud 0, Queyron PC, et al. Close monitoring ofserum HBV DNA levels and liver enzymes levels is most usefulin the management of patients with occult HBV infection [ J ]. JHepatol,2009,51(4); 824-825.
  • 2黄彬,陈茶,陈利达.乙型肝炎病毒基因型检测及其临床意义[J].中华医院感染学杂志,2011,21(9):1749-1751. 被引量:5
  • 3Els0e S,AhnstrOm J,Christoffersen C,et al. Apolipoprotein Mbinds oxidized phospholipids and increases the antioxidanteffect of HDL[J]. Atherosclerosis,2012,221 (1) :91-97.
  • 4AIM-HIGH Investigators, Boden WE, Probstfield JL’et al.Niacin in patients with low HDL cholesterol levels receivingintensive statin therapy [J]. N Engl J Med,2011,365(24) :2255-2267.
  • 5He XX,Chang Y,Jiang HJ,et al.Persistent effect of IFNAR-1genetic polymorphism on the long-term pathogenesis of chronicHBV infection [J]. Viral Immunol, 2010,23(3): 251-257.
  • 6Hansen BE,Buster EH,Steyerberg EW,et al. Prediction of theresponse to peg-interferon-alfa in patients with HBeAg positivechronic hepatitis B using decline of HBV DNA during treatment[J]. J Med Virol,2010,82(7) :1135-1142.
  • 7刘铁梅,王涵,李梓萌.乙型肝炎病毒前C区A1896基因突变的检测方法及临床意义[J].中华医院感染学杂志,2011,21(10):1971-1974. 被引量:8
  • 8Wang L,Liu H,Ning X,et al. Sequence analysis of the S generegion in HBV DNA from patients positive for both HBsAg andHBsAb tests[J]. Hepatol Res,2010,40( 12) : 1212-1218.
  • 9Shi F, Zhang JY,Zeng Z, et al. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosisin patients with HBV-related acute-on-chronic liver failure [J].Biochem Biophys Res Commun, 2010,402( 1 ) ; 30-36.
  • 10陆惠芬,李寒英,赵勤英.体检人群高密度脂蛋白水平与性别、年龄及常见慢性病的关系[J].浙江医学,2005,27(1):66-67. 被引量:2

二级参考文献35

  • 1Mamun-Al Mahtab,Salimur Rahman,Mobin Khan,Fazal Karim.Hepatitis B virus genotypes:an overview[J].Hepatobiliary & Pancreatic Diseases International,2008,7(5):457-464. 被引量:25
  • 2庄辉.乙型肝炎流行病学研究进展[J].国外医学(流行病学.传染病学分册),2004,31(3):133-135. 被引量:149
  • 3姚光弼,张定凤,王宝恩,徐道振,周霞秋,雷秉钧.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究[J].中华肝脏病杂志,2005,13(7):484-487. 被引量:117
  • 4Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1927
  • 5卢亦路,王玲,张发强,陈清英,夏增亮,胡迪,夏庆杰.成都地区HBV基因型分布研究[J].中华微生物学和免疫学杂志,2007,27(6):546-548. 被引量:7
  • 6Davey S. State of the World's Vaccines and Immunization [M]. Geneva:World Health organization,1996:76.
  • 7Alexopoulou A, karayiannis P, Hadziyamis SJ,et al. Whole genome analysis B virus form four case of folminant hepatitis: genetic varizbiliby and its potential role in disease pathogeniel- ty[J]. J Viral Hepatol,1996,3(4):173-181.
  • 8Kuwahara R, Kumashiro R, Murashima S, et al. Precore stop eodon mutation of hepatitis B virus is associated wit h low breakthrough rate following longterm lamivudine thera- py[J]. J Gast roenterol Hepatol,2005,20(6) :844-849.
  • 9Chen CH, Lee CM, Lu SN,et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-pos- itive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy[J]. J Hepatol, 2006,44 (1) 76-82.
  • 10Lok AS, Lai CL, Leung N, et al. Long-term safety of lami- vudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003,125 (6) :1714-1722.

共引文献12

同被引文献29

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部